pLVX-TetOne-Puro-hAXL Citations (8)
Originally described in: AXL Is a Putative Tumor Suppressor and Dormancy Regulator in Prostate Cancer.Axelrod HD, Valkenburg KC, Amend SR, Hicks JL, Parsana P, Torga G, DeMarzo AM, Pienta KJ Mol Cancer Res. 2019 Feb;17(2):356-369. doi: 10.1158/1541-7786.MCR-18-0718. Epub 2018 Oct 5. PubMed Journal
Articles Citing pLVX-TetOne-Puro-hAXL
| Articles |
|---|
Chromosomal instability accelerates the evolution of resistance to anti-cancer therapies.
Lukow DA, Sausville EL, Suri P, Chunduri NK, Wieland A, Leu J, Smith JC, Girish V, Kumar AA, Kendall J, Wang Z, Storchova Z, Sheltzer JM.
Dev Cell. 2021 Sep 13;56(17):2427-2439.e4. doi: 10.1016/j.devcel.2021.07.009. Epub 2021 Aug 4.
PubMed
Associated Plasmids |
| The oncoprotein BCL6 enables solid tumor cells to evade genotoxic stress. Liu Y, Feng J, Yuan K, Wu Z, Hu L, Lu Y, Li K, Guo J, Chen J, Ma C, Pang X. Elife. 2022 May 3;11:e69255. doi: 10.7554/eLife.69255. PubMed |
| Transcriptome Analysis of Diffuse Large B-Cell Lymphoma Cells Inducibly Expressing MyD88 L265P Mutation Identifies Upregulated CD44, LGALS3, NFKBIZ, and BATF as Downstream Targets of Oncogenic NF-kappaB Signaling. Turi M, Anilkumar Sithara A, Hofmanova L, Zihala D, Radhakrishnan D, Vdovin A, Knapkova S, Sevcikova T, Chyra Z, Jelinek T, Simicek M, Gulla A, Anderson KC, Hajek R, Hrdinka M. Int J Mol Sci. 2023 Mar 15;24(6):5623. doi: 10.3390/ijms24065623. PubMed |
| Pan-cancer Genomic Analysis of AXL Mutations Reveals a Novel, Recurrent, Functionally Activating AXL W451C Alteration Specific to Myxofibrosarcoma. Williams EA, Vegas I, El-Senduny FF, Zhang J, Mata DA, Hiemenz MC, Hughes SR, Sa BC, Kraft GP, Gorbatov N, Foley-Peres K, Sanchez EZ, Milikowski C, Williams KJ, Ross JS, Kurzrock R, Montgomery EA, Lombard DB, Kumar S. Am J Surg Pathol. 2024 Jun 1;48(6):699-707. doi: 10.1097/PAS.0000000000002191. Epub 2024 Feb 19. PubMed |
| Development of an orally bioavailable mSWI/SNF ATPase degrader and acquired mechanisms of resistance in prostate cancer. He T, Cheng C, Qiao Y, Cho H, Young E, Mannan R, Mahapatra S, Miner SJ, Zheng Y, Kim N, Zeng VZ, Wisniewski JP, Hou S, Jackson B, Cao X, Su F, Wang R, Chang Y, Kuila B, Mukherjee S, Dukare S, Aithal KB, D S S, Abbineni C, Lyssiotis CA, Parolia A, Xiao L, Chinnaiyan AM. bioRxiv [Preprint]. 2024 Mar 2:2024.02.29.582768. doi: 10.1101/2024.02.29.582768. PubMed |
| Development of an orally bioavailable mSWI/SNF ATPase degrader and acquired mechanisms of resistance in prostate cancer. He T, Cheng C, Qiao Y, Cho H, Young E, Mannan R, Mahapatra S, Miner SJ, Zheng Y, Kim N, Zeng VZ, Wisniewski JP, Hou S, Jackson B, Cao X, Su F, Wang R, Chang Y, Kuila B, Mukherjee S, Dukare S, Aithal KB, D S S, Abbineni C, Vaishampayan U, Lyssiotis CA, Parolia A, Xiao L, Chinnaiyan AM. Proc Natl Acad Sci U S A. 2024 Apr 9;121(15):e2322563121. doi: 10.1073/pnas.2322563121. Epub 2024 Apr 1. PubMed |
| A genetically encoded bifunctional enzyme mitigates redox imbalance and lipotoxicity via engineered Gro3P-Glycerol shunt. Pan X, Munan S, Zuckerman AL, Pon A, Violante S, Cross JR, Shah H, Cracan V. bioRxiv [Preprint]. 2025 Jun 5:2025.06.02.657195. doi: 10.1101/2025.06.02.657195. PubMed |
| Increased ErbB2 Signaling Is an Early Adaptation to Androgen Signaling Inhibition and Persists in Castration-Resistant Prostate Cancer. Owiredu J, Ersoy-Fazlioglu B, Poluben L, Calagua C, Dennehy C, Stavridi AM, Wang L, Voznesensky O, Xie F, Ye H, Sun Y, Einstein DJ, Gao X, Mantia C, Taplin ME, Muller WJ, Balk SP, Russo JW. Clin Cancer Res. 2025 Nov 3;31(21):4598-4610. doi: 10.1158/1078-0432.CCR-22-3683. PubMed |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.